Luminol

Currently, chronic recurrent cystitis is one of the most important problems in urology. Considering the role of immune status disorders in the pathogenesis of inflammatory diseases, the use of immunocorrective drugs as part of the complex therapy is of particular relevance.

to study the efficiency of therapy for chronic recurrent bacterial cystitis in combination with immunomodulators (Galavit).

A total of 60 women with acute stage of chronic recurrent bacterial cystitis were examined. The patients were randomized into 2 groups of 30 patients. In the control group, standard antibiotic therapy was administered. In the treatment group, patients received Galavit in combination with standard therapy. All patients were followed-up on the 1st, 5th and 10th day. Voiding diaries, chronobiological status and pain severity using a 5-point scale were evaluated. In addition, complete blood count, urinalysis, urine culture and enzyme immunoassay for determination of serum level of interleukin (IL) 1, IL-6, tumor necrosis factor (TNF-) were analyzed. A number of recurrences after 3 months of therapy was assessed.

Complex therapy in combination with Galavit in women with acute stage of chronic bacterial cystitis allows to decrease in desynchronosis by 20%, reduce pain by 2.5 times, frequency of urination by 1.7 times, the number of urgent voids and night urination by 2.4 and 5 times, respectively, by the 5th day of therapy. In the group of patients receiving immunomodulators a significantly more pronounced decrease in the level of IL-1, IL-6, TNF- and CRP was noted. During 3 months of follow-up, there were 2 recurrences in the control group and no recurrences in treatment group (10%).

The use of Galavit in the treatment of women with chronic recurrent bacterial cystitis has pathogenetic basis. A clear advantage of the drug is more rapid relief of symptoms, normalization of laboratory parameters, recovery of chronorhythms and the achievement of clinical remission.

to study the evolution of the oxidant-antioxidant homeostasis indices in patients with eczema using various methods of treating dermatosis. The study involved 63 patients with eczema (34 - males, 28 - females), aged 18-67 years, who were determined indices of pro- and antioxidant systems of blood. Patients with eczema were divided into 3 groups that were prescribed different treatments: the first comparative group (21 patients) - received a standard therapy; the second comparative group (20 patients) - had a standard therapy and additionally an antioxidant preparation "Mexidol", the third (basic group) - 22 patients, who were prescribed a complex therapy with a combination of two drugs with antioxidant effect: "Mexidol" and "Galavit." It was established that multimodality therapy for eczema while using two drugs with antioxidant action ("Mexidol", "Galavit") contributes to the most significant positive dynamics and normalization of the studied parameters of oxidant-antioxidant homeostasis of patients compared to a standard therapy of dermatosis or its combination with antioxidant preparation "Mexidol".